Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Vaccines
New vaccines study findings have been reported from University of Padua
July 16th, 2008
New investigation results, 'Clostridium difficile TxAC314 and SLP-36kDa enhance the immune response toward a co-administered antigen,' are detailed in a study published in Journal of Medical Microbiology. "This study evaluated the in vivo adjuvant activity of two peptides derived from Clostridium difficile: a fragment of the receptor-binding domain of toxin A (TxA(C314)) and a fragment of the 36 kDa surface-layer protein (SLP-36kDa) from strain C253," investigators in Padua, Italy report. "Their ability to affect the magnitude, distribution and polarization of the immune response against fibronectin-binding protein A (FnbpA), a protective vaccine antigen...
Source: Vaccine Weekly (2008-07-16)
|
